Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)
Status:
Completed
Trial end date:
2017-09-25
Target enrollment:
Participant gender:
Summary
The primary hypothesis was that obeticholic acid (OCA) will cause a reduction in alkaline
phosphatase levels in PBC participants, over a 12-week treatment period, as compared to
placebo.